Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13247376 | 0.91 | LMNA (0.53) | LMNACYP2C19HIF1A | |
| SCHEMBL10044867 | 0.89 | LMNA (0.64) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL10455518 | 0.88 | LMNA (0.61) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL3752378 | 0.87 | LMNA (0.63) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL3663722 | 0.87 | LMNA (0.63) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL9194179 | 0.86 | LMNA (0.50) | LMNACYP2C19HIF1A | |
| SCHEMBL13247531 | 0.85 | LMNA (0.61) | LMNACYP2C19HIF1AMAP2K2MAP2K1 | |
| SCHEMBL3066368 | 0.85 | LMNA (0.49) | LMNACYP2C19HIF1A | |
| SCHEMBL10044856 | 0.85 | LMNA (0.51) | LMNACYP2C19HIF1A | |
| SCHEMBL10044858 | 0.84 | LMNA (0.52) | LMNACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-8124806-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-02-28 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
| US-20090053142-A1 | CONTRAST AGENTS | WYNN DUNCAN | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053142-A1 | CONTRAST AGENTS | IPO4, TPO, IPO11 | LMNA 2151/4885CYP2C19 4077/4885HIF1A 860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.